A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Soft Tissue Sarcoma

Trial Profile

A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Soft Tissue Sarcoma

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Anlotinib (Primary)
  • Indications Alveolar soft part sarcoma; Clear cell sarcoma; Leiomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Therapeutic Use
  • Acronyms ALTER0203
  • Sponsors Chia Tai Tianqing Pharmaceutical Group
  • Most Recent Events

    • 23 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2017.
    • 23 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2017.
    • 23 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top